Na Li , MD
Welcome,         Profile    Billing    Logout  
 1 Trial 
6 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Li, Na
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting
3
560
RoW
Irinotecan Hydrochloride Injection, HX008, Placebo
Taizhou Hanzhong biomedical co. LTD
Stomach Cancer
08/23
08/23
SUNRAY-02, NCT06890598: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Recruiting
3
700
Europe, Japan, US, RoW
Olomorasib, LY3537982, Pembrolizumab, Durvalumab, Placebo
Eli Lilly and Company, AstraZeneca
Carcinoma, Non-Small-Cell Lung
05/29
02/32
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2/3
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc., Galectin Therapeutics Inc
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
03/25
09/25
NCT05022654: SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

Recruiting
2
40
RoW
SI-B001, Irinotecan
Sichuan Baili Pharmaceutical Co., Ltd.
Esophageal Squamous Cell Carcinomas
06/25
06/25
NCT05866510: Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer

Recruiting
2
47
RoW
Utidelone and anlotinib
Peking University, Beijing Biostar Pharmaceuticals Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Esophageal Cancer
04/24
04/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Li, Na
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting
3
560
RoW
Irinotecan Hydrochloride Injection, HX008, Placebo
Taizhou Hanzhong biomedical co. LTD
Stomach Cancer
08/23
08/23
SUNRAY-02, NCT06890598: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Recruiting
3
700
Europe, Japan, US, RoW
Olomorasib, LY3537982, Pembrolizumab, Durvalumab, Placebo
Eli Lilly and Company, AstraZeneca
Carcinoma, Non-Small-Cell Lung
05/29
02/32
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2/3
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc., Galectin Therapeutics Inc
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
03/25
09/25
NCT05022654: SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

Recruiting
2
40
RoW
SI-B001, Irinotecan
Sichuan Baili Pharmaceutical Co., Ltd.
Esophageal Squamous Cell Carcinomas
06/25
06/25
NCT05866510: Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer

Recruiting
2
47
RoW
Utidelone and anlotinib
Peking University, Beijing Biostar Pharmaceuticals Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Esophageal Cancer
04/24
04/24

Download Options